What is the recommended treatment for urinary tract infections (UTIs) during pregnancy using Macrobid (nitrofurantoin)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 9, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Macrobid (Nitrofurantoin) for UTI in Pregnancy

Nitrofurantoin is an appropriate and effective treatment for UTIs during pregnancy, particularly as a first-line agent for uncomplicated lower urinary tract infections and asymptomatic bacteriuria, but should be avoided near term (after 38 weeks gestation) due to theoretical risk of neonatal hemolytic anemia. 1

Treatment Recommendations by Trimester

First and Second Trimester

  • Nitrofurantoin is recommended as first-line therapy for uncomplicated UTIs and asymptomatic bacteriuria during the first and second trimesters 1
  • Fosfomycin (3g single dose) serves as an acceptable alternative 1
  • Treatment duration should be 7-14 days to ensure complete eradication 1
  • Always obtain a urine culture before initiating treatment to guide therapy 1

Third Trimester (Before 38 Weeks)

  • Nitrofurantoin can be used safely in early third trimester 1
  • After 38 weeks gestation, avoid nitrofurantoin due to theoretical risk of hemolytic anemia in neonates with G6PD deficiency 1

Alternative Agents When Nitrofurantoin is Contraindicated

  • Cephalexin 500 mg four times daily for 7-14 days is the preferred alternative 1
  • Cephalosporins (cephalexin, cefpodoxime, cefuroxime) achieve excellent blood and urinary concentrations with proven safety profiles 1
  • Amoxicillin-clavulanate is appropriate if the pathogen is susceptible 1

Critical Clinical Context

Why Treatment Matters

  • Untreated bacteriuria increases pyelonephritis risk 20-30 fold (from 20-35% to 1-4% with treatment) 2
  • Treatment reduces premature delivery and low birth weight infants 2
  • Implementation of screening programs decreased pyelonephritis rates from 1.8-2.1% to 0.5-0.6% 2

Safety Profile of Nitrofurantoin

  • Over 35 years of clinical use with continuing safety record 3
  • Animal studies at 2-6 times human therapeutic doses showed no maternal, fetal, or neonatal adverse effects 4
  • Retrospective analysis of 91 pregnancies showed no drug-related abnormal events, with outcomes similar to general US population 5
  • Highly effective for prophylaxis: reduced 130 UTIs pre-pregnancy to only 1 UTI during pregnancy in women with recurrent infections 6

Agents to Avoid

First Trimester Contraindications

  • Avoid trimethoprim and trimethoprim-sulfamethoxazole due to potential teratogenic effects including anencephaly, heart defects, and orofacial clefts 1, 7
  • Avoid fluoroquinolones throughout pregnancy due to potential adverse effects 1

Pyelonephritis Exception

  • Do not use nitrofurantoin for suspected pyelonephritis as it does not achieve therapeutic bloodstream concentrations 1
  • Use cephalosporins or other agents that achieve adequate blood levels for systemic infections 1

Follow-Up Protocol

  • Obtain follow-up urine culture 1-2 weeks after completing treatment to confirm cure 1
  • For recurrent UTIs, consider prophylactic cephalexin for remainder of pregnancy 1
  • Women with Group B Streptococcus bacteriuria require treatment at diagnosis plus intrapartum prophylaxis during labor 1

Common Pitfall

Despite ACOG 2011 recommendations suggesting caution with nitrofurantoin in first trimester, the extensive safety data and guideline support demonstrate it remains a first-line option. The key restriction is avoiding use after 38 weeks gestation, not during early pregnancy. 1, 7

References

Guideline

Treatment of UTI During Pregnancy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Nitrofurantoin: an update.

Obstetrical & gynecological survey, 1989

Research

Effective prophylaxis for recurrent urinary tract infections during pregnancy.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1992

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.